Showing results (241-250 of 554) with videos related to

Sort By:
Pageof 56
European Urology Open Science|June 9, 2022
Clinical Efficacy of Bipolar Androgen Therapy in Men with Metastatic Castration-Resistant Prostate Cancer and Combined Tumor-Suppressor LossMark C Markowski, Hao Wang, Angelo M De Marzo, et al.
JCO Precision Oncology|May 23, 2024
Prevalence and Spectrum of <i>AR</i> Ligand-Binding Domain Mutations Detected in Circulating-Tumor DNA Across Disease States in Men With Metastatic Castration-Resistant Prostate CancerEmmanuel S Antonarakis, Nicole Zhang, Jayati Saha, et al.
European Urology|October 20, 2018
Clinical Features and Therapeutic Outcomes in Men with Advanced Prostate Cancer and DNA Mismatch Repair Gene MutationsEmmanuel S Antonarakis, Farah Shaukat, Pedro Isaacsson Velho, et al.
JCO Precision Oncology|February 23, 2024
Pan-Cancer Interrogation of <i>MUTYH</i> Variants Reveals Biallelic Inactivation and Defective Base Excision Repair Across a Spectrum of Solid TumorsChanning J Paller, Hanna Tukachinsky, Alexandra Maertens, et al.
Cold Spring Harbor Molecular Case Studies|June 18, 2021
Mismatch repair-deficient prostate cancer with parenchymal brain metastases treated with immune checkpoint blockadeLaura A Sena, Daniela C Salles, Elizabeth L Engle, et al.
The Prostate|January 24, 2020
Extreme responses to immune checkpoint blockade following bipolar androgen therapy and enzalutamide in patients with metastatic castration resistant prostate cancerMark C Markowski, Eugene Shenderov, Mario A Eisenberger, et al.
BJU International|February 18, 2014
Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxelPhilipp Nuhn, Ajay M Vaghasia, Jatinder Goyal, et al.
The New Phytologist|November 12, 2025
Legacies of model initialization on predictions of future ecosystem dynamics in California's Sierra Nevada: insights from GEDILi-Ling Chang, Shaoqing Liu, Alexander S Antonarakis, et al.
BJU International|June 19, 2012
The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancerJatinder Goyal, Philipp Nuhn, Peng Huang, et al.
European Urology Oncology|December 5, 2024
Recent and Future Developments in the Use of Poly (ADP-ribose) Polymerase Inhibitors for Prostate CancerFrancesca Zacchi, Wassim Abida, Emmanuel S Antonarakis, et al.
Pageof 56